Apnimed Announces $62.5 Million Series C Financing To Advance Development Of Novel Pharmaceutical Treatments For Obstructive Sleep Apnea (Osa) And Related Sleep Disorders
Apnimed Announces $62.5 Million Series C Financing To Advance Development Of Novel Pharmaceutical Treatments For Obstructive Sleep Apnea (Osa) And Related Sleep Disorders
05/04/22, 10:30 AM
Location
cambridgeMoney raised
$62.5 million
Round Type
series c
Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today that it has raised $62.5 million of committed capital in a Series C financing. New investor, Sectoral Asset Management, led the round. Also participating were new investors Alpha Wave Ventures, NexPoint, and others, joining existing investors Morningside Ventures, Seligman Investments, and Tao Capital Partners.
Company Info
Location
cambridge, maryland, united states
Additional Info
Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea – patients with obstructive sleep apnea could benefit from treatment with a safe and effective oral medication dosed once daily at bedtime. Apnimed’s lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep. Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders. Learn more at apnimed.com or follow us on Twitter and LinkedIn.